Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors

Colby S. Shemesh,Yongsheng Wang,Andrew An,Hao Ding,Phyllis Chan,Qi Liu,Yih-Wen Chen,Benjamin Wu,Qiong Wu,Xian Wang

DOI: https://doi.org/10.1007/s00280-024-04650-y

2024-03-08

Cancer Chemotherapy and Pharmacology

Abstract:Tiragolumab is an immunoglobulin G1 monoclonal antibody targeting the immune checkpoint T cell immunoreceptor with immunoglobulin and immunoreceptor ITIM domains. Targeting multiple immune pathways may improve anti-tumor responses. The phase I YP42514 study assessed the pharmacokinetics (PK), safety, and preliminary efficacy of tiragolumab plus atezolizumab in Chinese patients with advanced solid tumors.

oncology,pharmacology & pharmacy

What problem does this paper attempt to address?

What problems does this paper aim to solve?

The main purpose of this paper is to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of the combined use of Tiragolumab and Atezolizumab in Chinese patients with advanced solid tumors. Specifically, the study attempts to answer the following key questions:

1. **Pharmacokinetic characteristics**: Are the pharmacokinetic characteristics of Tiragolumab and Atezolizumab in Chinese patients similar to those in the global population? This includes the absorption, distribution, metabolism, and excretion of the drugs.

2. **Safety**: What is the safety of the combined treatment of Tiragolumab and Atezolizumab in Chinese patients? Are there any specific adverse events or toxic reactions?

3. **Preliminary efficacy**: Does the combined treatment of Tiragolumab and Atezolizumab show preliminary anti - tumor activity in Chinese patients? Specifically, it is manifested by indicators such as objective response rate (ORR) and disease control rate (DCR).

4. **Ethnic sensitivity analysis**: By comparing the pharmacokinetic and safety data of Chinese patients with those of patients in other parts of the world, evaluate whether there are ethnic differences, so as to provide a basis for future clinical trial design and drug development.

### Research background

Malignant tumors are one of the main causes of death in China, and the incidence has been rising continuously since 2000. In recent years, China's drug regulatory environment has changed, encouraging more innovative drug research and development, and requiring ethnic sensitivity analysis in the early stage of drug development to bridge the gap between global clinical data and the Chinese population. The combined use of immune checkpoint inhibitors (ICI) such as Tiragolumab and Atezolizumab aims to enhance the anti - tumor immune response by simultaneously blocking the TIGIT and PD - L1 pathways.

### Research methods

This phase I clinical trial named YP42514 is an open - label study, recruiting adult patients with advanced or metastatic solid tumors from mainland China. Patients received intravenous injections of Tiragolumab (600 mg) and Atezolizumab (1200 mg) every three weeks until unacceptable toxicity occurred or clinical benefit was lost. The primary endpoint of the study was the serum concentrations of Tiragolumab and Atezolizumab, and the secondary endpoints included immunogenicity and efficacy evaluation.

### Conclusion

The study shows that the combined treatment of Tiragolumab and Atezolizumab is well - tolerated in Chinese patients and shows preliminary anti - tumor activity. The pharmacokinetic and safety data are similar to those in the global population, and no significant ethnic differences were found. These results provide an important reference for further clinical trials.

### Key formulas

- **Pharmacokinetic parameters**:
- Maximum plasma concentration \(C_{\text{max}}\)
- Minimum serum concentration \(C_{\text{min}}\)
- Area under the curve \(AUC_{0 - 21}\) and \(AUC_{0-\infty}\)
- Clearance rate \(CL\)
- Volume of distribution \(V_{ss}\)
- Half - life \(t_{1/2}\)

These parameters are used to describe the behavior of drugs in the body and are summarized by geometric mean (GM) and coefficient of variation (%CV). For example:

\[ \text{GMR}_{AUC_{0 - 21}}=\frac{\text{Cycle 1 tiragolumab AUC}_{0 - 21} \text{ in Chinese patients}}{\text{Cycle 1 tiragolumab AUC}_{0 - 21} \text{ in global patients}} = 1.07\]

This indicates that the pharmacokinetic characteristics of Chinese patients are basically the same as those of global patients.